Source comparison
Tesamorelin + Ipamorelin Blend Dosage: Research Application Comparison
GH secretion baseline assessment 100mcg each peptide, single dose Fasted state, morning or pre-sleep Single administration 40–80% above baseline at 60–90 min Minimal dose establishes receptor responsiveness without desensitization risk Body composition researc
This comparison does not assign a generated winner or score.
- GH secretion baseline assessment
- 100mcg each peptide, single dose
- Fasted state, morning or pre-sleep
- Single administration
- 40–80% above baseline at 60–90 min
- Minimal dose establishes receptor responsiveness without desensitization risk
- Body composition research (lean mass / adipose reduction)
- 200–300mcg each peptide daily
- 30–60 min before sleep
- 12–16 weeks
- 60–120% sustained elevation
- Requires concurrent resistance stimulus and caloric management for outcome validity
- IGF-1 restoration in aging models
- 200mcg each peptide daily
- Pre-sleep administration
- 8–12 weeks minimum
- 50–100% elevation from depressed baseline
- Lower doses sufficient when baseline IGF-1 is already suppressed vs. healthy young models
- Comparative secretagogue efficacy study
- 100–300mcg titration vs. control
- Standardized circadian timing
- 4–8 weeks with washout periods
- Dose-dependent; plateau at 300mcg
- Dual-pathway activation (GHRH + ghrelin) produces 3–5× greater AUC than single-agent protocols
- Metabolic dysfunction research (insulin sensitivity, lipid metabolism)
- 200mcg each peptide 5 days/week
- Pre-sleep, non-consecutive rest days
- 12+ weeks
- Sustained 70–110% elevation
- Pulsatile dosing (5 on / 2 off) prevents receptor downregulation better than continuous daily administration